Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FDHT PET Imaging in Advanced Breast Cancer
NCT06145399Phase 1Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of 18F-FDHT in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of lesions that correlate 18F-FDHT uptake with IHC expression of AR. Planned start Oct 2023; status: withdrawn.
02
Drugs
18F-FDHT
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06145399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145399.